AstraZeneca Pharma India and Mankind Pharma have entered into an agreement for exclusive distribution of AstraZeneca’s budesonide and formoterol fumarate dihydrate (inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination) brand Symbicort in India. AstraZeneca will retain the intellectual property rights to budesonide and formoterol fumarate dihydrate and will continue to be the Marketing Authorisation Holder (MAH) and import license.
With an expansive distribution network including close to 16,000 field force and more than 13,000 stockists across India, Mankind Pharma has positioned itself as a leader in ensuring availability and access to quality pharmaceuticals across the country, including small towns and rural areas.
AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1735.45 |
Dr. Reddys Lab | 1144.05 |
Cipla | 1441.70 |
Lupin | 2026.50 |
Zydus Lifesciences | 885.70 |
View more.. |